U.S. markets close in 3 hours 38 minutes
  • S&P 500

    4,113.33
    +50.29 (+1.24%)
     
  • Dow 30

    34,031.49
    +443.83 (+1.32%)
     
  • Nasdaq

    13,135.26
    +103.58 (+0.79%)
     
  • Russell 2000

    2,152.95
    +17.82 (+0.83%)
     
  • Crude Oil

    63.98
    -2.10 (-3.18%)
     
  • Gold

    1,825.30
    +2.50 (+0.14%)
     
  • Silver

    27.08
    -0.16 (-0.60%)
     
  • EUR/USD

    1.2083
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.6630
    -0.0320 (-1.89%)
     
  • GBP/USD

    1.4036
    -0.0021 (-0.15%)
     
  • USD/JPY

    109.5410
    -0.1190 (-0.11%)
     
  • BTC-USD

    50,255.64
    -4,609.79 (-8.40%)
     
  • CMC Crypto 200

    1,369.24
    -18.67 (-1.34%)
     
  • FTSE 100

    6,963.33
    -41.30 (-0.59%)
     
  • Nikkei 225

    27,448.01
    -699.50 (-2.49%)
     

Sanofi/Regeneron's Libtayo Wins FDA Approval For A Type Of Skin Cancer

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) immunotherapy Libtayo (cemiplimab-rwlc) has scored approval from the FDA for the treatment of advanced basal cell carcinoma (BCC), the most common type of skin cancer in the U.S.

  • The FDA has indicated Libtayo for treating previously-treated, advanced BCC patients who have already received a hedgehog pathway inhibitor (HHI) or who cannot be treated with an HHI.

  • The PD-1 inhibitor has been granted full approval for patients with locally advanced BCC and accelerated approval for patients with metastatic BCC, which has spread to other parts of the body.

  • In 2018, Libtayo was approved as the first systemic treatment for metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

  • Price Action: REGN closed 0.8% down at $490.68, while, SNY closed 0.5% higher at $48.86.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.